Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)Tip Ranks·Jul 19 at 07:15 AMTNGX-2.31%
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga_article·Jul 15 at 05:59 AMTNGX-2.31%FISN-7.78%
The Great Uncoupling: Defense Tech Thrives While Consumer Stocks ScrambleGlobal Report·Jul 14 at 06:47 AMLITB-1.57%ZTO-0.25%
Tango Therapeutics President, R&D Crystal Adam disposes of common shares worth $798,704PUBT·Jul 2 at 06:24 PMTNGX-2.31%
Tango Therapeutics director Robert Azelby files initial beneficial ownership statementPUBT·Jun 23 at 05:04 PMTNGX-2.31%
As AbbVie eyes Apogee, these biotech stocks earn the highest quant ratingsMSN·Jun 22 at 08:55 AMNTLA-0.27%LEGN0.00%
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option GrantedTradingView·Jun 10 at 04:23 PMTNGX-2.31%JPM+0.49%
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering | TNGX Stock NewsStockTitan·Jun 9 at 01:49 PMTNGX-2.31%
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data ProspectsSimplywall·Jun 9 at 12:33 AMTNGX-2.31%
